Recombinant Chlorocebus aethiops Sterol O-acyltransferase 1 (SOAT1)

What is the primary function of SOAT1 in cellular metabolism?

SOAT1 (Sterol O-acyltransferase 1) is an enzyme that catalyzes the formation of cholesterol esters (CEs) from free cholesterol (FC) and fatty acids, playing a fundamental role in cellular cholesterol homeostasis. This esterification process helps prevent the accumulation of excessive free cholesterol, which can be toxic to cells . SOAT1 activity is particularly important in conditions where cholesterol metabolism is dysregulated, such as in metabolic disorders and cancer. Research has demonstrated that SOAT1 inhibition reduces cellular CE levels and can increase ABCA1-mediated cholesterol efflux, suggesting its critical role in regulating intracellular cholesterol balance .

How does SOAT1 differ from other enzymes involved in lipid metabolism?

SOAT1 belongs to a family that includes SOAT2, but these enzymes exhibit distinct tissue distribution and functional profiles in research models. While SOAT1 has broader tissue expression patterns and is associated with multiple cancer types, SOAT2 shows more restricted expression profiles . Notably, in hepatocellular carcinoma (HCC), SOAT1 mRNA levels are dramatically higher than SOAT2, and SOAT1 amplification is more common than SOAT2 alterations . Unlike enzymes such as DGAT1 and DGAT2 (which primarily esterify diacylglycerols), SOAT1 specifically targets cholesterol for esterification, making it a unique mediator of cholesterol homeostasis . Additionally, SOAT1 functions in a metabolic network with enzymes like CPT1A, which regulates fatty acid oxidation, forming a regulatory feedback loop that maintains lipid balance in cells .

What experimental models are suitable for studying recombinant SOAT1 function?

Several experimental models have proven effective for studying recombinant SOAT1 function. In vitro models include human podocyte cell lines, where SOAT1 inhibition has been shown to increase ABCA1 expression and reduce cytotoxicity . Primary cell cultures derived from experimental animal models, such as primary podocytes from African green monkey kidney tissue, can be established to study SOAT1 activity under various conditions . For in vivo studies, several mouse models have been developed, including SOAT1 knockout mice (Soat1−/−) which demonstrate decreased cholesterol ester content and altered physiological responses . Additionally, disease-specific models such as diabetic nephropathy models (db/db mice) and Alport syndrome mice crossed with SOAT1-deficient mice have been successfully employed to investigate SOAT1's role in disease progression .

What are the molecular mechanisms by which SOAT1 promotes epithelial-mesenchymal transition (EMT) in cancer cells?

SOAT1 promotes EMT in cancer cells through dysregulation of cholesterol metabolism. Research on hepatocellular carcinoma (HCC) has revealed that SOAT1 facilitates EMT by maintaining cholesterol homeostasis through two primary mechanisms: increased cholesterol in the plasma membrane and accumulation of cholesterol esters . These alterations in cholesterol distribution affect membrane fluidity and lipid raft composition, which subsequently influence signaling pathways that drive EMT. Analysis of SOAT1's molecular interactions suggests it activates multiple pathways linked to cancer progression, including PI3K/AKT signaling, IL-18 signaling, calcium signaling, Wnt signaling, and JAK/STAT pathways . The connection between SOAT1 and EMT is further supported by correlation studies showing that SOAT1 expression positively associates with EMT markers in HCC tissues, and experimental models demonstrate that SOAT1 inhibition can reverse the EMT phenotype by normalizing cholesterol metabolism .

How does SOAT1 interact with the immune microenvironment in pathological conditions?

SOAT1 expression significantly influences the tumor immune microenvironment through complex interactions with multiple immune cell populations. Bioinformatic analyses have revealed that SOAT1 expression positively correlates with the abundance of specific immune cells, including macrophages, Th2 cells, T helper cells, CD56bright natural killer cells, and Th1 cells . Conversely, SOAT1 expression negatively correlates with Th17 cells, dendritic cells, and cytotoxic cells . These associations suggest that SOAT1 may modulate immune surveillance and anti-tumor responses by altering the composition and function of tumor-infiltrating immune cells. The mechanisms behind these correlations likely involve SOAT1's role in lipid metabolism, as altered cholesterol homeostasis affects immune cell function, particularly in lipid raft-dependent signaling pathways crucial for immune cell activation and cytokine production. This immunomodulatory role of SOAT1 provides a rationale for combining SOAT1 inhibitors with immunotherapeutic approaches in cancer treatment.

What is the significance of the SOAT1-CPT1A regulatory axis in cellular metabolism?

The SOAT1-CPT1A regulatory axis represents a sophisticated metabolic control mechanism that maintains lipid homeostasis in cells. Bioinformatic analysis has revealed that SOAT1-mediated fatty acid storage and CPT1A-mediated fatty acid oxidation (FAO) form a double-negative feedback loop, particularly in hepatocellular carcinoma . When CPT1A (Carnitine Palmitoyltransferase 1A) is inhibited, excess fatty acids are diverted toward storage in lipid droplets through SOAT1-mediated esterification. Conversely, SOAT1 inhibition enhances CPT1A protein expression, which shuttles the released fatty acids into mitochondria for oxidation . This reciprocal regulation between SOAT1 and CPT1A is particularly critical in cancer cells, which often rely on reprogrammed lipid metabolism to support their growth and survival. Gene expression analysis shows that genes negatively correlated with SOAT1 are primarily involved in fatty acid metabolism, oxidation-reduction processes, and respiratory chain complexes, while CPT1A positively correlates with lipid oxidation and tricarboxylic acid cycle components . This metabolic axis presents a promising target for therapeutic intervention, as simultaneous targeting of both enzymes has demonstrated synergistic anticancer efficacy in HCC models .

What are the optimal conditions for expressing and purifying recombinant Chlorocebus aethiops SOAT1?

The expression and purification of recombinant Chlorocebus aethiops SOAT1 requires careful optimization due to its membrane-associated nature. Based on research protocols with similar proteins, effective expression systems include baculovirus-infected insect cells or mammalian expression systems that can properly fold and post-translationally modify this complex protein. The purification process typically involves detergent solubilization of membranes containing the expressed SOAT1, followed by affinity chromatography using appropriate tags (His, FLAG, or GST) engineered into the recombinant construct. Critical parameters for maintaining SOAT1 activity during purification include pH maintenance between 7.2-7.6, inclusion of glycerol (10-15%) in buffers, and the addition of protease inhibitors to prevent degradation. Activity assays measuring the conversion of radiolabeled cholesterol to cholesterol esters can confirm the functionality of the purified protein. For applications requiring insertion of SOAT1 into artificial membranes, reconstitution into liposomes or nanodiscs has proven effective in maintaining enzymatic activity while providing a controlled lipid environment that mimics physiological conditions.

How can researchers accurately measure SOAT1 enzymatic activity in experimental models?

Accurate measurement of SOAT1 enzymatic activity in experimental models requires methods that specifically quantify the conversion of free cholesterol to cholesterol esters. One established approach involves incubating cell lysates or purified SOAT1 with 14C-labeled oleoyl-CoA and measuring the incorporation of the radioactive label into cholesterol esters through thin-layer chromatography or high-performance liquid chromatography . For in vitro studies using cell cultures, researchers can extract total lipids and separate cholesterol esters from free cholesterol using techniques such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) . The cholesterol ester content can then be quantified and normalized to total cellular protein.

Alternative methods include fluorescent-based assays using NBD-cholesterol (22-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3β-ol) as a substrate, which allows for real-time monitoring of esterification activity. When conducting SOAT1 activity assays, it is crucial to include appropriate controls, such as specific SOAT1 inhibitors (e.g., avasimibe) to confirm the specificity of the measured activity . For in vivo studies, cholesterol ester content in tissues can be quantified following lipid extraction, with particular attention to the kidney cortex or liver tissue depending on the disease model being studied .

What techniques are effective for analyzing SOAT1 expression in tissue samples?

Multiple complementary techniques provide comprehensive analysis of SOAT1 expression in tissue samples. Quantitative real-time PCR (qRT-PCR) effectively measures SOAT1 mRNA levels, allowing researchers to detect changes in expression under different experimental conditions or disease states . This technique has successfully demonstrated increased SOAT1 expression in podocytes exposed to sera from patients with progressive diabetic kidney disease compared to non-progressive cases .

For protein-level analysis, Western blotting with specific anti-SOAT1 antibodies provides quantitative measurement of SOAT1 protein expression and can detect post-translational modifications. Immunohistochemistry (IHC) is particularly valuable for localizing SOAT1 expression within tissue architecture and has been used to create scoring systems (0-3) based on staining intensity and percentage of positive cells . In cancer research, SOAT1 protein expression patterns assessed by IHC have been correlated with clinical outcomes and pathological features . For more precise localization, immunofluorescence combined with confocal microscopy allows co-localization studies with other cellular markers.

For large-scale analysis, tissue microarrays enable simultaneous analysis of SOAT1 expression across multiple tissue samples. Digital pathology tools can then quantify expression patterns using standardized algorithms, reducing subjective interpretation. When analyzing SOAT1 expression data, it is important to normalize to appropriate reference genes or proteins and to include relevant clinical and pathological correlations for meaningful interpretation .

How can SOAT1 inhibition be leveraged in developing therapeutic strategies for kidney disease?

SOAT1 inhibition presents a promising therapeutic approach for kidney diseases, particularly diabetic kidney disease (DKD) and Alport syndrome (AS). Research has demonstrated that SOAT1 inhibition protects podocytes from injury by reducing cholesterol ester (CE) accumulation and increasing ABCA1/APOA1-mediated cholesterol efflux . Several methodological approaches can be implemented to leverage SOAT1 inhibition therapeutically.

Small molecule inhibitors targeting SOAT1, such as the SOAT1 inhibitor (SI) used in experimental models, have shown efficacy in preventing podocyte cytotoxicity and apoptosis when exposed to sera from patients with progressive kidney disease . In vivo studies using genetic models (Soat1−/− mice) have demonstrated improved renal function and reduced disease progression in experimental models of DKD and AS . These models show decreased cholesterol ester content in kidney cortices, increased ABCA1 expression in glomeruli, and decreased mesangial expansion compared to control mice .

The efficacy of SOAT1 inhibition appears to be partially mediated through ABCA1-dependent mechanisms, as demonstrated by experiments with ABCA1 knockdown podocytes where the protective effect of SOAT1 inhibition was reduced . This suggests that combination strategies enhancing both SOAT1 inhibition and ABCA1-mediated cholesterol efflux could provide synergistic therapeutic benefits. The translational potential of this approach is supported by evidence that SOAT1 deficiency preserves podocyte numbers in diabetic models, directly addressing a critical pathological feature of progressive kidney disease .

What is the prognostic value of SOAT1 expression in cancer and how can it guide personalized treatment approaches?

In HCC, SOAT1 expression is also associated with poor prognosis. Bioinformatic analysis revealed that SOAT1 has higher expression in tumor tissues compared to adjacent normal tissues, with an area under the ROC curve of 0.748 when comparing tumor samples to para-carcinoma tissues . This elevated expression correlates with lower survival rates in HCC patients .

The prognostic value of SOAT1 can guide personalized treatment approaches in several ways. For ACC, SOAT1 expression may help identify patients more likely to benefit from mitotane therapy, as SOAT1 is a molecular target for this drug . In HCC, SOAT1 expression correlates with immune cell infiltration patterns, suggesting potential integration with immunotherapy approaches . Patients with high SOAT1 expression might benefit from combination therapies targeting both SOAT1 and immune checkpoints.

Furthermore, the connection between SOAT1 and CPT1A in lipid metabolism suggests that simultaneous targeting of multiple metabolic pathways could be effective in patients with high SOAT1 expression . The combination of SOAT1 inhibitors (like avasimibe) with FAO inhibitors (like etomoxir) has demonstrated synergistic anticancer efficacy in HCC models and represents a promising personalized approach for patients with altered lipid metabolism .

How does SOAT1 contribute to metastasis and what methodological approaches can be used to study this process?

SOAT1 contributes to metastasis primarily through promoting epithelial-mesenchymal transition (EMT), a critical process in cancer cell invasion and metastatic spread. Research on hepatocellular carcinoma has demonstrated that SOAT1 positively correlates with EMT markers and promotes cell migration and invasion in vitro . The underlying mechanism involves SOAT1-mediated disruption of cholesterol metabolism homeostasis, specifically through increased cholesterol in the plasma membrane and accumulation of cholesterol esters .

Several methodological approaches can effectively study SOAT1's role in metastasis. In vitro migration and invasion assays using Transwell chambers or wound-healing assays can quantify the metastatic potential of cancer cells with manipulated SOAT1 expression. These approaches have demonstrated that SOAT1 overexpression enhances migration and invasion capabilities, while SOAT1 knockdown or inhibition reduces these metastatic behaviors .

Molecular analysis of EMT markers (E-cadherin, N-cadherin, Vimentin, etc.) through Western blotting, immunofluorescence, and qRT-PCR provides mechanistic insights into how SOAT1 regulates the EMT program. Membrane cholesterol content can be measured using filipin staining or extraction followed by enzymatic quantification to correlate SOAT1 activity with membrane cholesterol levels, a key factor in EMT signaling .

In vivo metastasis models, including orthotopic xenografts with subsequent analysis of distant organ colonization, offer physiologically relevant systems to study SOAT1's impact on metastasis. These models can be combined with SOAT1 inhibitors or genetic manipulation (knockdown/overexpression) to assess therapeutic potential. Notably, natural compounds like nootkatone have been identified to inhibit EMT by targeting SOAT1 both in vitro and in vivo, providing promising leads for anti-metastatic therapy .

What are the emerging roles of SOAT1 in metabolic reprogramming beyond cholesterol homeostasis?

SOAT1's functions extend beyond cholesterol homeostasis to influence broader aspects of cellular metabolism. Emerging research indicates that SOAT1 plays crucial roles in metabolic reprogramming through its interactions with key metabolic pathways and signaling cascades. Gene Set Enrichment Analysis (GSEA) has revealed that genes negatively correlated with SOAT1 are primarily involved in oxidation-reduction processes and respiratory chain complex activity, suggesting SOAT1 may influence mitochondrial function and energy metabolism .

The interaction between SOAT1 and CPT1A represents a significant metabolic regulatory mechanism, forming a double-negative feedback loop that balances fatty acid storage and oxidation . This regulatory axis has implications for cellular energy production and utilization beyond simple lipid storage. Additionally, SOAT1's role in modulating membrane lipid composition affects numerous membrane-associated signaling pathways, including PI3K/AKT signaling, which is a master regulator of cellular metabolism .

In non-alcoholic fatty liver disease (NAFLD) progression to HCC, SOAT1 appears to contribute to the metabolic adaptations that facilitate tumor development . The enzyme's activity increases in response to high-fat diet conditions, suggesting a role in adapting to nutrient excess and metabolic stress . Future research should explore how SOAT1 interfaces with other metabolic sensing pathways, such as AMPK and mTOR signaling, and investigate its potential roles in regulating autophagy, a key process in cellular adaptation to metabolic stress.

How can structural insights into SOAT1 from Chlorocebus aethiops inform the development of species-specific inhibitors?

Structural analysis of Chlorocebus aethiops SOAT1 can provide valuable insights for developing species-specific inhibitors with enhanced efficacy and reduced off-target effects. Although detailed structural information about SOAT1 is currently limited, comparative sequence analysis between primate species can identify conserved catalytic domains and species-specific variations. These variations may reside in substrate binding pockets or allosteric regulatory sites that could be exploited for selective targeting.

Advanced structural biology techniques, including cryo-electron microscopy and X-ray crystallography of purified recombinant SOAT1, would significantly advance our understanding of the enzyme's three-dimensional structure. Homology modeling based on related enzymes with known structures can provide preliminary structural insights while experimental structures are being determined. Molecular docking studies using these structural models can then identify potential binding sites for inhibitor development.

Site-directed mutagenesis experiments comparing the effects of mutations in conserved versus variable regions between species can validate structural predictions and identify functionally important residues. Enzymatic assays comparing inhibitor efficacy across SOAT1 from different species can establish structure-activity relationships and guide optimization of species-selective compounds. Development of species-specific inhibitors would be particularly valuable for preclinical testing, allowing researchers to predict human responses more accurately based on comparative pharmacology across primate models.

What biomarker panels could be developed that incorporate SOAT1 expression for improved disease stratification?

Integrating SOAT1 expression into comprehensive biomarker panels could significantly enhance disease stratification in multiple conditions. For cancer prognostication, particularly in adrenocortical carcinoma and hepatocellular carcinoma, combining SOAT1 expression with established markers could improve risk stratification. In ACC, SOAT1 could be incorporated with Ki-67 proliferation index and SF-1 expression, which has also shown prognostic value . For HCC, a panel including SOAT1, AFP, and markers of vascular invasion could provide more accurate prognostic information .

For kidney disease progression, combining SOAT1 expression with markers of podocyte injury (nephrin, podocin) and inflammation could help identify patients at higher risk for rapid progression who might benefit from targeted therapies . Using machine learning algorithms to integrate multiple biomarkers, including SOAT1 expression, clinical parameters, and genetic factors, could generate personalized risk scores with higher predictive value than individual markers alone.

Liquid biopsy approaches measuring circulating tumor DNA methylation patterns of SOAT1 or SOAT1 expression in circulating tumor cells could provide minimally invasive monitoring tools. Multi-omics integration of SOAT1 expression with metabolomic profiles (particularly cholesterol derivatives and fatty acids) could provide functional context to expression changes and improve biological interpretation. Development and validation of these integrated biomarker panels would require prospective clinical studies with standardized measurement protocols and appropriate statistical modeling to account for the interactions between multiple markers.